# To Screen or Not to Screen

**Show Floor, Sky Stage**  
October 10, 2023  
Vivien Ho  
Pear VC  
Andrew Lacy  
Prenuvo  
Everett Cunningham  
Exact Sciences  
Megan Hall, Ph.D.  
GRAIL, LLC  
Peter B. Bach, M.D.  
DELFI Diagnostics

HTLH sessions summaries are sponsored by Abridge, the leader in real-time generative AI for clinical documentation. For a demo of the Abridge solution - used by thousands of clinicians every day - see us at booth 5923. Video summaries are generated by a third party.

This discussion involved a panel of leaders from various healthcare firms such as Grail, Prova Healthcare, Delphi Diagnostics, and Exact Sciences who are pioneering the fields of prevention and detection in oncology. Topics covered include disparities in cancer detection, ease of tests, effective partnerships with health systems and payers, the need for rigorous evidence for tests and regulations and speed of innovation. They agree that the system needs to better accommodate transformative, rather than just incremental, change, and that tests need to be affordable and accessible for all patients. Moreover, they highlighted the critical importance of evidence and the role of regulatory bodies in ensuring the efficacy of new cancer screening tests. The discussion also touched on how digital health can empower patients to ask for cutting-edge care.

The HLTH team is processing the video. Your summary will be ready soon. Check back later.